Abbott’s new 2-in-1 continuous glucose monitor (CGM) offers hope for diabetics by measuring both glucose and ketone levels. But as this tech becomes more sophisticated, will it truly stand out in a crowded market or just join the ranks of gadgets that fizzled out?
My own brush with ketoacidosis as a teenager serves as a stark reminder of why such monitoring is crucial. But Dr. David Ahn highlights that while ketone monitoring is more common for children, it could be a game-changer for insulin pump users and those on SGLT2 inhibitors.
The Libre Duo’s ability to function as a 'check engine light' could be a significant breakthrough, especially for managing Type 1 diabetes. Yet, the challenges of data accuracy and interpretation remain, as countless diabetic subreddits testify. Can this tech navigate the pitfalls of wearable tech hype and deliver on its promises?
In an age where fitness trackers and smartwatches are ubiquitous, Abbott’s new CGM must prove its value beyond just another gadget. Its success will depend on whether it can not only measure but also meaningfully impact the lives of those it aims to help.
